CASE Op-Ed in DC Journal: Cutting Healthcare Red Tape Should Not Mean Cutting Corners on Consumers’ Health
The quest to cut overly burdensome government regulations as a means to spark economic activity is a cause to which...
The quest to cut overly burdensome government regulations as a means to spark economic activity is a cause to which...
The House Budget Committee’s recent hearing, “Breaking Up Health Care Monopolies: Examining the Budgetary Effects of Health Care Consolidation,” brought...
September 1, 2023 The rise of pharmacy benefit managers (PBMs) has transformed them into the dominant force in U.S....
June 20, 2023 The 118th Congress is off to a great start in shining a light on the harmful practices...
December 4, 2022 The senators’ mention of pharmacy services was especially interesting, given the recent cut of pharmacy services...
Military members, veterans, and their families are devastated by Express Scripts dropping nearly 15,000 local and independent pharmacies to boost...
October 23, 2022 In a desperate attempt to reshape the narrative, President Biden hosted a celebration last month for...
July 6, 2022 After months and months of petty negotiations over Build Back Better, Democrats have finalized a dangerous...
May 12, 2022 A well-intentioned but ineffective proposal that would force drug manufacturers to post the price of prescription...
February 28, 2022 Mark Cuban is making headlines, and not for the reason you’d think. The billionaire investor seized...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/